Indical Bioscience acquires Salmonella and antimicrobial resistance diagnostics company - Veterinary Practice
Your browser is out-of-date!

Update your browser to view this website correctly. Update my browser now

×

Indical Bioscience acquires Salmonella and antimicrobial resistance diagnostics company

Indical Bioscience, part of Vimina’s diagnostic segment, has signed an agreement to acquire Check-Points, the Dutch molecular diagnostics company specialising in Salmonella typing for food and veterinary sectors

Indical Bioscience, the operating company within Vimian’s diagnostics segment, has signed an agreement to acquire Check-Points. Check-Points is a Dutch molecular diagnostics company specialising in Salmonella typing for the food and veterinary market as well as antimicrobial resistance detection for human applications.

Check-Points is a Dutch research and development focused company that produces tests for two principal markets – food safety and human antimicrobial resistance. The main component of the business is related to “Check and Trace”, a unique product based on a microarray platform to accurately identify over 300 serotypes of Salmonella. The company, founded in 2002 with annual revenues of approximately EUR 2.3 million, also produces a number of DNA-based tests for the molecular detection of antimicrobial resistance in hospital acquired infections in humans.

Through the Salmonella test, the company principally serves producers and labs within the poultry industry as well as food safety labs. The human assays principally target in-hospital laboratories.

“The acquisition of Check-Points bolsters our poultry portfolio and direct-to-producer offering but also represents a first step for Indical into food safety and antimicrobial resistance segments. Check-Points has developed strong momentum in its core products and has an exciting R&D pipeline, with highly relevant development expertise that can support new projects within Indical itself. We look forward to working with the Check-Points management team to take advantage of all these opportunities”, says Stefano Santarelli, CEO of Indical Bioscience.

“Joining forces with Indical will allow us to extend the worldwide footprint of our unique, innovative products. We are excited about this wonderful opportunity for our company”, says Pieter Vos, CEO of Check-Points.

The acquisition will have a marginal impact on Vimian Group AB’s earnings per share in the current financial year.

Veterinary Practice

Veterinary Practice is an online knowledge and information hub for veterinary professionals across all specialties. It provides reliable, useful and interesting content, written by expert authors and covering small animal, large animal, equine and practice management sectors of the veterinary surgeon and nursing professions.


More from this author

Have you heard about our
IVP Membership?

A wide range of veterinary CPD and resources by leading veterinary professionals.

Stress-free CPD tracking and certification, you’ll wonder how you coped without it.

Discover more